- Home
- SRPT vs VOR Comparison
SRPT vs VOR Comparison
Compare SRPT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRPT | VOR |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 813.3M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SRPT | VOR |
|---|---|---|
| Price | $16.20 | $13.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 29 | 10 |
| Target Price | $25.85 | ★ $45.33 |
| AVG Volume (30 Days) | ★ 2.8M | 788.6K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.88 | N/A |
| Revenue | ★ $2,198,237,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.64 | ★ N/A |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $10.42 | $0.18 |
| 52 Week High | $43.92 | $49.95 |
Technical Indicators
Market Signals| Indicator | SRPT | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 33.89 | 40.46 |
| Support Level | $15.70 | $11.74 |
| Resistance Level | $19.62 | $16.87 |
| Average True Range (ATR) | 0.76 | 0.83 |
| MACD | -0.07 | -0.16 |
| Stochastic Oscillator | 6.77 | 6.58 |
Price Performance
Historical ComparisonAbout SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.